A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer

被引：3
作者：
Yamashita, Toshinari [1 ]
Shimomura, Akihiko [2 ]
Takano, Toshimi [3 ]
Sagara, Yasuaki [4 ]
Watanabe, Junichiro [5 ]
Tokunaga, Eriko [6 ]
Kikumori, Kunika [7 ]
Kamiyama, Emi [7 ]
Kamio, Takahiro [7 ]
Nakamura, Ryo [7 ]
Shinkai, Tetsu [8 ]
Takahashi, Shunji [9 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Shonan Tobu Sougou Hosp, Kamakura, Kanagawa, Japan
[9] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-12
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
    Yamaguchi, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S235 - S235
  • [42] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
    Iwata, Hiroji
    Tamura, Kenji
    Doi, Toshihiko
    Tsurutani, Junji
    Modi, Shanu
    Park, Haeseong
    Krop, Ian E.
    Sagara, Yasuaki
    Redfern, Charles H.
    Murthy, Rashmi Krishna
    Redman, Rebecca A.
    Shitara, Kohei
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Kim, Sung-Bae
    Chung, Wei-Pang
    Im, Seock-Ah
    Park, Yeon Hee
    Hegg, Roberto
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Petry, Vanessa
    Chung, Chi-Feng
    Iwata, Hiroji
    Hamilton, Erika
    Curigliano, Giuseppe
    Xu, Binghe
    Lee, Caleb
    Liu, Yali
    Cathcart, Jillian
    Bako, Emarjola
    Verma, Sunil
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [44] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Jhaveri, Komal
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Darilay, Annie
    Gao, Chen
    Patel, Gargi
    Wrona, Magdalena
    Andre, Fabrice
    CANCER RESEARCH, 2021, 81 (04)
  • [45] Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-hee
    Sakai, Daisuke
    Chung, Hyun Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Trastuzumab deruxtecan (DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study
    Andre, F.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Krop, I. E.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
    Borghaei, Hossein
    Besse, Benjamin
    Bardia, Aditya
    Mazieres, Julien
    Popat, Sanjay
    Augustine, Bincy
    D'amelio, Anthony Michael
    Barrios, Daniel
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [50] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies
    Li, Claire
    Henning, Stefanie
    Patel, Kashyap
    Hui, Katrina
    van der Vleuten, Gerly
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
12345